CTAGE7P: A Potential Drug Target and Biomarker (G119437)

Target Name: CTAGE7P

NCBI ID: G119437

CTAGE7P

CTAGE7P: A Potential Drug Target and Biomarker

CTAGE7P is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. Its function is not well understood, but it is known to play a role in the development and progression of certain diseases, such as cancer. The potential drug target and biomarker properties of CTAGE7P make it an attractive target for researchers to investigate.

Disease-Causation Interpretation

The involvement of CTAGE7P in various diseases has led to its potential as a drug target. One of the main objectives of drug development is to identify compounds that can modulate the activity of CTAGE7P and prevent or reverse its negative effects on disease progression. This is achieved by conducting high-throughput screening experiments, such as cell-based assays, in which potential drugs can be evaluated for their ability to interact with CTAGE7P and modulate its activity.

One of the potential benefits of targeting CTAGE7P is its potential to serve as a biomarker for disease diagnosis and monitoring. The expression of CTAGE7P is known to be regulated in various diseases, including cancer, and its levels can be used as a biomarker to monitor disease progression and response to treatment. This is an important aspect of drug development, as it allows researchers to monitor the effectiveness of drugs and determine their potential for use in different diseases.

Another potential benefit of targeting CTAGE7P is its potential to modulate cellular processes that are involved in disease progression. CTAGE7P has been shown to play a role in the regulation of cell adhesion, which is a process that is involved in the formation and maintenance of tissues and organs. This is an important aspect of disease development, as changes in cell adhesion can contribute to the development and progression of various diseases.

Chemical Characterization

The chemical characterization of CTAGE7P is an important step in its development as a drug target and biomarker. The studies have shown that CTAGE7P is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is characterized by a predicted molecular weight of 41 kDa and a calculated pI of 6.9.

The expression of CTAGE7P has been shown to be regulated in various diseases, including cancer. For example, studies have shown that overexpression of CTAGE7P has been associated with the development of cancer, while its downregulation has been shown to protect against cancer development. This suggests that CTAGE7P may play a negative role in the development and progression of cancer, and that its modulation may be a potential drug target.

High-Throughput Screening

High-throughput screening (HTS) is a powerful tool for identifying potential drugs that can modulate the activity of CTAGE7P. HTS experiments involve the use of cell-based assays, in which potential drugs are evaluated for their ability to interact with CTAGE7P and modulate its activity. These assays can be divided into two main categories: cell-based assays and biochemical assays.

Cell-based assays, such as the cell-attached receptor (CAR) assay, can be used to evaluate the ability of potential drugs to interact with CTAGE7P and modulate its activity. In this assay, cells are grown on a scaffold and the drugs are applied to the cells, and the activity of the drug is measured by measuring the activity of a specific protein, such as

Protein Name: CTAGE Family Member 7, Pseudogene

The "CTAGE7P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTAGE7P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets